Sevikar HCT - treatment opportunity for patients with essential hypertension - SeviTarget
Phase of Trial: Phase IV
Latest Information Update: 28 May 2019
At a glance
- Drugs Olmesartan medoxomil/amlodipine/hydrochlorothiazide (Primary)
- Indications Essential hypertension
- Focus Adverse reactions
- Acronyms SeviTarget
- Sponsors Daiichi Sankyo Europe
- 03 Apr 2014 Status changed from active, no longer recruiting to completed as reported by German Clinical Trials Register.
- 11 Dec 2013 Status changed from recruiting to active, no longer recruiting as reported by German Clinical Trials Register.
- 21 Jan 2013 New trial record